Week of May 6, 2019 | Vol. 8, Issue 18
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.
Health Catalyst to Raise $150M to $200M in IPO
Share listing would bring company with patient health-record data to public markets
Health-data company Health Catalyst Inc. is planning to raise $150 million to $200 million in its initial public offering, according to people familiar with the matter, bringing one of the first digital-health companies to public markets as technology startups race to list shares. Health Catalyst, a health-data storage and software company, said in mid-April it had confidentially filed paperwork with the Securities and Exchange Commission for the IPO. The filing follows Health Catalyst’s latest fundraising earlier this year, which valued the company at $1 billion. Valuations and amounts companies seek to raise can change as they get closer to going public. The Salt Lake City company is one of the latest technology firms aiming to go public this year. Ride-hailing rivals  Lyft  Inc. and Uber Technologies Inc., online image board  Pinterest Inc. and workplace-messaging app Slack Technologies Inc. have entered public markets—or plan to—in 2019.

 C ontinue Reading at The Wall Street Journal.
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
14 transactions totaling $1,876 million
Supplies, Equipment & Services
26 transactions totaling $7,306 million
Healthcare IT & Managed Care
4 transactions totaling $6 million
Healthcare Facilities & Distributors
19 transactions totaling $205 million
Pharma & Biotech
24 transactions totaling $480 million
Supplies, Equipment & Services
19 transactions totaling $112 million
Healthcare IT & Managed Care
6 transactions totaling $46 million
Healthcare Facilities & Distributors
0 transactions
Pharma & Biotech
23 transactions totaling $1,330million
Supplies, Equipment & Services
4 transactions totaling $239 million
Healthcare IT & Managed Care
0 transactions
Healthcare Facilities & Distributors
2 transactions totaling $116 million
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
May 2, 2019 - Bio Space
With its acquisition of Shire now under its belt, Takeda Pharmaceutical is building up its research and development presence in the United States.Earlier this week, the company announced it has opened a new research facility in San Diego. The new 165.000 square foot site is home to more than 250 employees focused on leveraging specialized drug discovery technologies and advancing discovery research in gastroenterology and neuroscience, the company said.

May 1, 2019 - Fierce Biotech
Eisai is buying Purdue Pharma’s stake in sleep disorder drug lemborexant. The deal gives Eisai sole responsibility for global development and commercialization of a drug that is nearing FDA approval. Purdue bought a stake in the Eisai-discovered dual orexin receptor antagonist in 2015 and co-funded phase 3 development.

April 30, 2019 - Fierce Pharma
Merck & Co.’s cancer wunderkind Keytruda continues to turn in supercharged sales, $2.27 billion in the first quarter, which bodes well for the future of biologics manufacturing jobs at the company. But woe to those who work at other facilities, because the company has undertaken a manufacturing restructuring that could cost up to $1.2 billion when the dust settles.

April 29, 2019 - Bio Space
Calixar , based in Lyon France, announced it had inked a licensing deal with Regeneron Pharmaceuticals . There are few specifics about the licensing agreement. Calixar is providing Regeneron exclusive rights to its technology and expertise. Regeneron plans to work on developing antibodies against an undisclosed target in several different therapeutic areas.
Recent Materials Providing Insight Into Healthcare Related Industries